A new FDA-approved drug for Alzheimer’s signals a breakthrough in innovation for patients and caregivers, but has raised doubts from some over the price tag and approval process. Confused about what all of this means for you? This episode breaks it down.
Dr. Bob walks listeners through the accelerated approval process while Terry looks at the role this plays in future medical innovation. Sue Peschin, President and CEO of the Alliance for Aging Research, explains how the price tag fits into the ongoing debate over drug pricing policies. And we hear from Allison Wilson, who gives a caregiver’s perspective as she reflects on her mother’s diagnosis of early-onset Alzheimer’s.
Dr. Robert Goldberg, “Dr. Bob,” Co-Founder and Vice President of the Center for Medicine in the Public Interest
Allison Wilson, Caregiver
Becky Brandt, Patient Correspondent
The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands? Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.org
Have a question or comment about the show, or want to suggest a show topic or share your story as a patient correspondent?
Drop us a line: email@example.com
The views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising.